Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer

Cancer

Volumn 119, Issue 21, 2013, Pages 3746-3752

  Love, Richard R ^a   Young, Gregory S ^b   Laudico, Adriano V ^c   Van Dinh, Nguyen ^d   Uy, Gemma B ^c   Quang, Le Hong ^d   De La Peña, Arturo S ^c   Dofitas, Rodney B ^c   Bisquera, Orlino C ^c   Siguan, Stephen S S ^e   Salvador, Jonathan D S ^f   Mirasol Lumague, Maria Rica ^g   Navarro, Narciso S ^h   Linh, Nguyen Dieu ^d   Jarjoura, David ^b  

^a International Breast Cancer Foundation   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c PHILIPPINE GENERAL HOSPITAL   (Philippines)

^d Hospital K   (Viet Nam)

^e Vicente Soto Memorial Medical Center   (Philippines)

^f Rizal Medical Center ^*  (Philippines)

^g Rizal Medical Center   (Philippines)

^h UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

Author keywords

adjuvant drug therapy; bone mineral density; breast cancer; femoral neck; menopause; oophorectomy; spine; tamoxifen

Indexed keywords

TAMOXIFEN CITRATE;

ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; FEMUR NECK; FILIPINO; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTECTOMY; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; OVARIECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIETNAMESE;

EID: 84886102259     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28302     Document Type: Article

References (23)

1. Economist Intelligence Unit report, sponsored by Livestrong. Breakaway: The global burden of cancer-challenges and opportunities. http://www.livestrong. org/pdfs/GlobalEconomicImpact. August 2009.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
3. Love RR, Van Dinh N, Quy TT, et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol. 2008; 26: 253-257.
4. Robert H, Wang M, Cella D, et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node negative receptor-positive breast cancer ≤ 3 cm [Abstract]. Proc Am Soc Clin Oncol. 2003; 22: 5 (abstract 16).
5. Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol. 2005; 23: 5973-5982.
6. Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomised study. J Natl Cancer Inst. 2000; 92: 903-911.
7. Klijn JGM, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol. 2001; 19: 343-353.
8. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone- releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007; 369: 1711-1723.
9. Parton M, Smith IE,. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol. 2008; 26: 745-762.
10. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacologic intervention to prevent fractures. Arch Int Med. 2004; 164: 1108-1112.
11. WHO Scientific Group. Prevention and Management of Osteoporosis. WHO Technical Report Series 921. Geneva, Switzerland: World Health Organization; 2003.
12. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992; 326: 852-856.
13. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996; 14: 78-84.
14. Eastell R, Admas J, Glack G, et al. Long term effects of anastrozole on bone mineral density: 7 year results from the ATC trial. Ann Oncol. 2011; 22: 857-862.
15. Sverrisdottir A, Fortnander H, Jabcobsson H, von Schoultz E, Rutqvist LE,. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004; 22: 3694-3699.
16. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007; 25: 820-828.
17. Shapiro CL, Manola J, Leboff M,. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in premenopausal women with early stage breast cancer. J Clin Oncol. 2001; 19: 3306-3311.
18. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998; 90: 704-708.
19. Saarto T, Blomqvist C, Valimaki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997; 15: 1341-1347.
20. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A,. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double blind, placebo-controlled study. J Clin Oncol. 1997; 15: 955-962.
21. Stevens W,. Asymptotic regression. Biometrics. 1951; 7: 247-267.
22. Love RR, Duc NB, Dinh NV, et al. Mastectomy and oophorectomy by menstrual cycle phase in operable breast cancer. J Natl Cancer Inst. 2002; 94: 662-669.
23. Love RR, Duc NB, Havighurst TC, et al. HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol. 2003; 21: 453-457.